Clinical trial NCT03192696: Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries
Official title: INSIGHT: EvaluatIoN of the PantheriS OCT- ImaGing AtHerectomy SysTem For Treatment of In-Stent Restenosis (ISR) Lesions In Lower Extremity Arteries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Avinger, Inc.
Sponsor class: INDUSTRY
First posted: 2017-06-20
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A prospective, non-randomized, international, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent Restenotic (ISR) lesions in lower extremity arteries.

Detailed description: This is a prospective, global, single-arm, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy of in-stent restenotic (ISR) lesions in lower extremity arteries.

The trial will enroll up to 140 subjects diagnosed with peripheral arterial disease of the lower extremities that have previously been treated with stenting at up to 20 sites. The primary disease must be located in reference vessel diameter of \>3.0mm and ≤7.0mm. Trial success is focused on safety, including rates of major adverse events through 30 days as adjudicated by a Clinical Events Committee, and effectiveness, which will be evaluated using technical success defined as the percent of target lesions that have residual diameter stenosis \<50% post-treatment with the Pantheris device alone as assessed by Angiographic Core Lab.

Eligibility criteria: Inclusion Criteria:

* Subject is \>18 years old;
* Subject is willing and able to give informed consent;
* Subject has Rutherford Classification of I-V;
* Subject presenting with a single Class I, II or III ISR lesion as per Tosaka's Classification criteria in the lower leg extremities;
* Target lesion must be \>70% stenosed and within a stented segment by angiographic visual estimation;
* Reference vessel lumen acceptable for treatment with Pantheris catheter size as per visual angiographic estimation;
* Target lesions must be within the stented segment and no more than 3 cm past the proximal or distal portions of the stent;
* Target lesion is ≤30 cm in length;
* Intraluminal crossing of totally occluded lesions prior to atherectomy;
* At least one patent tibial run-off vessel at baseline; and
* Subject is capable of meeting requirements and be present at the follow-up clinic visits at 30 days, 6 months and 12 months.

Exclusion Criteria:

* Subject is pregnant or breast feeding;
* Rutherford Class 0 or VI;
* Severe calcification of the target lesion;
* Acute ischemia and/or acute thrombosis of the target lesion segment;
* Target lesion with a covered stent;
* Target lesion in the iliac artery;
* Target lesion stenosis \<70%;
* Target lesion \>30 cm in length;
* Subjects with totally occluded stented segments that are not successfully crossed intraluminally prior to atherectomy treatment;
* Grade 4 or 5 stent fracture affecting target stent, or where evidence of stent protrusion into the lumen is noted on angiography in two orthogonal views;
* Subjects on chronic hemodialysis or creatinine level \>2.5 mg/dL;
* CVA or stroke within 60 days prior to the index procedure;
* Endovascular or surgical procedure performed on the index limb less than or equal to 30 days prior to the index procedure;
* Planned endovascular or surgical procedure 30 days after the index procedure;
* Lesion in the contralateral limb requiring intervention during the index
* procedure or within 30 days of the index procedure;
* Known allergy to contrast agents or medications used to perform endovascular
* intervention that cannot be adequately pre-treated;
* Subjects in whom anti-platelet, aspirin, anticoagulant, or thrombolytic therapy is contraindicated;
* Any thrombolytic therapy within 2 weeks of the index procedure;
* Any clinical and/or angiographic complication attributed to the use of another device prior to the insertion of the study device into the subject during the index procedure;
* Subjects or their legal guardians who have not or will not sign the Informed Consent;
* Subjects who are unwilling or unable to comply with the follow-up study
* requirements; or
* Participation in any study of an investigational device, medication, biologic or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of the study.

Primary outcomes:
measure: Freedom from a composite of major adverse events (MAEs) through 30-day follow-up (safety)
timeFrame: Day 0 through 30 days post treatment procedure
measure: Technical success of Pantheris catheter treatment (efficacy) device
timeFrame: Day 0
Secondary outcomes:
measure: Stent structure freedom from new or worsening stent fracture post Pantheris treatment (safety)
timeFrame: Day 0
measure: Secondary Effectiveness Endpoint - Freedom from TLR
timeFrame: 6 months post treatment procedure
measure: Secondary Effectiveness Endpoint - Procedural Success
timeFrame: Day 0
measure: Secondary Effectiveness Endpoint - Freedom from TLR
timeFrame: 12 months post treatment procedure
measure: Secondary Effectiveness Endpoint - Ankle-Brachial Index
timeFrame: 30 days, 6 and 12 months post treatment procedure
measure: Secondary Effectiveness Endpoint - Rutherford Classification
timeFrame: 30 days, 6 and 12 months post treatment procedure
measure: Secondary Effectiveness Endpoint - Use Adjunctive Devices
timeFrame: Day 0
Other outcomes:
Locations:
city: Jonesboro
country: United States
facility: St. Bernards Medical Center
state: Arkansas
city: Little Rock
country: United States
facility: Arkansas Heart Hospital
state: Arkansas
city: San Diego
country: United States
facility: University of California San Diego (UCSD)
state: California
city: Oak Lawn
country: United States
facility: Advocate Christ Hospital and Medical Center
state: Illinois
city: Baton Rouge
country: United States
facility: Baton Rouge General Medical Center
state: Louisiana
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
city: Browns Mills
country: United States
facility: Deborah Heart and Lung Center
state: New Jersey
city: Cincinnati
country: United States
facility: TriHealth-Hatton Research Institute
state: Ohio
city: Dayton
country: United States
facility: Dayton Heart Center
state: Ohio
city: Philadelphia
country: United States
facility: Einstein Medical Center
state: Pennsylvania
city: Memphis
country: United States
facility: University of Tennessee Health Science Center
state: Tennessee
city: Tyler
country: United States
facility: Cardiovascular Associates of East Texas
state: Texas
Study officials:
affiliation: Einstein Medical Center
name: Sean Janzer, MD
role: PRINCIPAL_INVESTIGATOR
References: